Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
149.16
+0.76 (0.51%)
At close: Jun 5, 2026, 4:00 PM EDT
148.00
-1.16 (-0.78%)
After-hours: Jun 5, 2026, 7:56 PM EDT
Novartis AG Employees
Novartis AG had 75,267 employees as of December 31, 2025. The number of employees decreased by 616 or -0.81% compared to the previous year.
Employees
75,267
Change (1Y)
-616
Growth (1Y)
-0.81%
Revenue / Employee
$751,697
Profits / Employee
$179,813
Market Cap
271.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,267 | -616 | -0.81% |
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
| Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
| Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
| Dec 31, 2016 | 118,393 | -307 | -0.26% |
| Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
| Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
| Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
| Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
| Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
| Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
| Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
| Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
| Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
| Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
| Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
| Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
| Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
| Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
| Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
| Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
| Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
| Dec 31, 1998 | 85,835 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
NVS News
- 1 day ago - Novartis AG (NVS) Shares Surge 3.3% -- What GF Score of 81 Tells Investors - GuruFocus
- 2 days ago - Novartis (NVS) Shows Promising Phase III ALIGN Study Results for Kidney Treatment - GuruFocus
- 2 days ago - Novartis Vanrafia Data Show Clinically Meaningful Kidney Protection In IgA Nephropathy - Nasdaq
- 2 days ago - Novartis reports final 2.5-year Phase III ALIGN results on Vanrafia - TheFly
- 2 days ago - Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years - GlobeNewsWire
- 2 days ago - Novartis Cosentyx Shows Sustained Remission In Polymyalgia Rheumatica - Nasdaq
- 3 days ago - Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients - GlobeNewsWire
- 5 days ago - Positive Long-Term Results for Scemblix in CML Trials (NVS) - GuruFocus